Skip to search formSkip to main contentSkip to account menu

Systemic Anaplastic Large Cell Lymphoma

Known as: ALCL, systemic, Anaplastic large-cell lymphoma, primary systemic type 
An anaplastic large cell lymphoma that is not confined to a single anatomic site and involves multiple nodal and/or extranodal sites.
National Institutes of Health

Related topics

Related topics

18 relations
AnaplasiaAtypical lymphocyteHematopoietic and Lymphoid CellHematopoietic and Lymphoid Tissue

Broader (1)

Ki-1+ Anaplastic Large Cell Lymphoma

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
The biology and management of systemic anaplastic large cell lymphoma.
Systemic anaplastic large cell lymphoma (ALCL) is an aggressive CD30(+) non-Hodgkin lymphoma. Anaplastic lymphoma kinase-positive… 
Review
2010
Review
2010
Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
Anaplastic large cell lymphoma (ALCL) is a biologic and clinically heterogenous subtype of T-cell lymphoma. Clinically, ALCL may… 
Highly Cited
2009
Highly Cited
2009
A Phase II study of SGN‐30 (anti‐CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
SGN‐30, a chimeric anti‐CD30 monoclonal antibody, has demonstrated potent preclinical antitumour activity in both Hodgkin… 
Highly Cited
2009
Highly Cited
2009
Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941
Anaplastic large cell lymphoma (ALCL) is characterized by advanced disease at presentation (70–80% of pediatric cases) and… 
Highly Cited
2004
Highly Cited
2004
Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma.
Anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma of T/null-cell immunophenotype, characterized by… 
Review
2003
Review
2003
ALK‐negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects–a review
Anaplastic large cell lymphoma (ALCL) can be divided into two major groups. The first is a spectrum of CD30+ T‐cell… 
2003
2003
Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma.
PURPOSE p27(Kip1)(p27) is a universal cyclin-dependent kinase inhibitor that inhibits cell cycle transition from G(1) to S phase… 
2003
2003
Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma.
Systemic anaplastic large cell lymphoma (ALCL) frequently carries the t(2;5)(p23;q35) and overexpresses anaplastic lymphoma… 
Highly Cited
2003
Highly Cited
2003
Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma
Primary cutaneous CD30+ anaplastic large cell lymphoma (C‐ALCL) represents a distinct clinical subtype of CD30+ anaplastic large… 
2002
2002
Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma.
A recent study by Wellmann et al (Blood. 2000;96:398-404) detected clusterin expression in all 36 systemic anaplastic large cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)